Addendum
Blinatumomab (B-ALL, high-risk first relapsed, children and adolescents >= 1 month) – Addendum to Project A26-60
Report documents
-
Addendum
Blinatumomab (B-ALL, high-risk first relapsed, children and adolescents >= 1 month) – Addendum to Project A26-60
Dossier assessment
Paediatric patients aged 1 month or older with high-risk first relapsed Philadelphia chromosome-negative CD19+ B-cell precursor acute lymphoblastic leukaemia, as part of the consolidation therapy
unchanged after addendum: indication of a major added benefit
Additional information
Federal Joint Committee (GBA)
19-11-2026 A G-BA decision was published.
GBA documents on this decision
Project details
- Project no.
- A26-121
- Commission
- Commission awarded on 06.10.2026 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Haematology
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
- DOI
https://doi.org/10.60584/A26-121
Connected Projects
-
Dossier assessment
Blinatumomab (B-ALL, high-risk first relapsed, children and adolescents >= 1 month) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed